SAN DIEGO—(BUSINESS WIRE)—Mar. 26, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in neurological and related centralnervous system disorders, today announced that Daniel Soland has joinedits Board of Directors. Mr. Soland is a seasoned pharmaceuticalexecutive with over 30 years of experience in the biopharmaceuticalindustry.
“Dan brings a tremendous wealth of commercial experience to the Boardand his perspective and insight will be welcomed as ACADIA advancesNUPLAZID™ towards registration and prepares for the plannedlaunch of NUPLAZID in the United States,” said Leslie L. Iversen, Ph.D.,Chairman of ACADIA’s Board of Directors. “In addition to his extensivecommercial experience in launching new drugs and life cycle management,he has led manufacturing and quality organizations and has beeninstrumental in driving growth in the companies he has served.”
Mr. Soland previously served as Senior Vice President and ChiefOperating Officer of ViroPharma starting in 2008 until it was acquiredin 2014, and as Vice President and Chief Commercial Officer of theCompany from 2006 to 2008. During his tenure at ViroPharma, Mr. Solandmanaged the commercial, manufacturing and quality organizations, helpedbuild the company’s commercial infrastructure in the United States,Europe, and Canada and led the launch of Cinryze®, one of themost successful ultra-orphan drugs in the United States. Mr. Solandserved as President, Chiron Vaccines, of Chiron Corporation from 2005 to2006 and led the growth of the vaccine business to over $1 billion insales. From 2002 through 2005, Mr. Soland served as President and ChiefExecutive Officer of Epigenesis Pharmaceuticals. Earlier in his career,Mr. Soland worked for GlaxoSmithKline in increasing roles ofresponsibility from 1993 to 2002, including as Vice President andDirector, Worldwide Marketing Operations, GSK Biologicals. He currentlyserves on the board of directors of Tarsa Therapeutics and DBVTechnologies SA. Mr. Soland earned his B.S. in Pharmacy from theUniversity of Iowa.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin neurological and related central nervous system disorders. ACADIA hasa pipeline of product candidates led by NUPLAZID (pimavanserin), forwhich we have reported positive Phase III trial results in Parkinson’sdisease psychosis and which has the potential to be the first drugapproved in the United States for this disorder. Pimavanserin is also inPhase II development for Alzheimer’s disease psychosis and hassuccessfully completed a Phase II trial in schizophrenia. ACADIA alsohas clinical-stage programs for chronic pain and glaucoma incollaboration with Allergan, Inc. All product candidates are smallmolecules that emanate from internal discoveries. ACADIA maintains awebsite at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the registration and planned launchof NUPLAZID (pimavanserin) for the treatment of Parkinson’s diseasepsychosis (PDP); the potential for pimavanserin to be the first drugapproved in the United States for PDP, if approved at all; and theprogress, timing and results of ACADIA’s drug discovery and developmentprograms, either alone or with a partner, including the progress andexpected timing of clinical trials. These statements are onlypredictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties related to those inherentin drug discovery, development, approval, and commercialization, andcollaborations with others, and the fact that past results of clinicaltrials may not be indicative of future trial results. For a discussionof these and other factors, please refer to ACADIA’s annual report onForm 10-K for the year ended December 31, 2014 as well as ACADIA’ssubsequent filings with the Securities and Exchange Commission. You arecautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Steve Davis, Interim ChiefExecutive Officer
Lisa Barthelemy, Director of InvestorRelations
(858) 558-2871